Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CAPR NASDAQ:NTLA NASDAQ:PHVS NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPRCapricor Therapeutics$7.06+9.0%$10.18$3.52▼$23.40$295.99M0.822.66 million shs1.84 million shsNTLAIntellia Therapeutics$13.60+6.4%$9.86$5.90▼$27.42$1.32B2.214.52 million shs4.11 million shsPHVSPharvaris$20.62+2.8%$18.41$11.51▼$26.33$1.05B-2.82155,395 shs709,620 shsWVEWAVE Life Sciences$8.40+0.1%$6.97$5.04▼$16.74$1.31B-1.011.60 million shs1.40 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPRCapricor Therapeutics-4.99%-9.50%-29.95%-50.27%+42.42%NTLAIntellia Therapeutics-10.25%+8.03%+33.54%+53.79%-50.08%PHVSPharvaris-3.79%-15.51%+16.57%+19.06%+12.26%WVEWAVE Life Sciences-1.99%+4.74%+22.84%+24.67%+36.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCAPRCapricor Therapeutics2.6504 of 5 stars4.61.00.00.01.60.80.6NTLAIntellia Therapeutics4.5653 of 5 stars4.31.00.04.73.22.50.6PHVSPharvaris1.4877 of 5 stars3.51.00.00.01.80.80.0WVEWAVE Life Sciences4.6105 of 5 stars3.52.00.04.83.44.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAPRCapricor Therapeutics 3.11Buy$22.56219.48% UpsideNTLAIntellia Therapeutics 2.65Moderate Buy$33.37145.36% UpsidePHVSPharvaris 3.00Buy$36.2075.56% UpsideWVEWAVE Life Sciences 2.92Moderate Buy$20.15139.93% UpsideCurrent Analyst Ratings BreakdownLatest CAPR, NTLA, WVE, and PHVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025WVEWAVE Life SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.007/14/2025CAPRCapricor TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/14/2025CAPRCapricor TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$31.00 ➝ $12.007/11/2025CAPRCapricor TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$20.007/11/2025CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$77.00 ➝ $24.006/30/2025CAPRCapricor TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.006/26/2025CAPRCapricor TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.006/25/2025CAPRCapricor TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/25/2025CAPRCapricor TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $29.006/24/2025CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$77.006/23/2025CAPRCapricor TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$43.00 ➝ $22.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAPRCapricor Therapeutics$22.27M14.48N/AN/A$3.20 per share2.21NTLAIntellia Therapeutics$57.88M24.34N/AN/A$8.56 per share1.59PHVSPharvarisN/AN/AN/AN/A$5.54 per shareN/AWVEWAVE Life Sciences$108.30M12.07N/AN/A$1.37 per share6.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAPRCapricor Therapeutics-$40.47M-$1.42N/AN/AN/A-181.71%-62.42%-48.36%8/6/2025 (Estimated)NTLAIntellia Therapeutics-$519.02M-$5.23N/AN/AN/A-1,154.10%-56.06%-44.25%8/14/2025 (Estimated)PHVSPharvaris-$145.24M-$3.01N/AN/AN/AN/A-54.02%-50.36%8/13/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.84N/AN/AN/AN/A-86.49%-37.20%7/30/2025 (Estimated)Latest CAPR, NTLA, WVE, and PHVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025NTLAIntellia Therapeutics-$1.03N/AN/AN/A$12.26 millionN/A8/13/2025Q1 2025PHVSPharvaris-$0.87N/AN/AN/AN/AN/A8/6/2025Q2 2025CAPRCapricor Therapeutics-$0.48N/AN/AN/A$2.60 millionN/A7/30/2025Q2 2025WVEWAVE Life Sciences-$0.28N/AN/AN/A$11.52 millionN/A5/13/2025Q1 2025CAPRCapricor Therapeutics-$0.33-$0.53-$0.20-$0.53$3.16 million$2.73 million5/13/2025Q1 2025PHVSPharvaris-$0.80-$0.89-$0.09-$0.89N/AN/A5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million5/8/2025Q1 2025WVEWAVE Life Sciences-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCAPRCapricor TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCAPRCapricor TherapeuticsN/A6.556.55NTLAIntellia TherapeuticsN/A4.904.90PHVSPharvarisN/A11.1011.10WVEWAVE Life SciencesN/A2.952.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAPRCapricor Therapeutics21.68%NTLAIntellia Therapeutics88.77%PHVSPharvarisN/AWVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipCAPRCapricor Therapeutics10.50%NTLAIntellia Therapeutics3.10%PHVSPharvaris11.84%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCAPRCapricor Therapeutics10145.68 million40.88 millionOptionableNTLAIntellia Therapeutics600103.58 million100.37 millionOptionablePHVSPharvaris3052.29 million46.10 millionNot OptionableWVEWAVE Life Sciences240155.56 million118.26 millionOptionableCAPR, NTLA, WVE, and PHVS HeadlinesRecent News About These CompaniesWAVE Life Sciences (WVE) to Release Quarterly Earnings on WednesdayJuly 25 at 4:42 PM | marketbeat.comNew York State Common Retirement Fund Acquires 41,429 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE)July 25 at 3:52 AM | marketbeat.comWave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025July 23 at 8:30 AM | globenewswire.comHussman Strategic Advisors Inc. Has $848,000 Stake in WAVE Life Sciences Ltd. (NASDAQ:WVE)July 19, 2025 | marketbeat.comPrincipal Financial Group Inc. Acquires 59,399 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE)July 19, 2025 | marketbeat.comBreaking Down WAVE Life Sciences: 4 Analysts Share Their ViewsJuly 16, 2025 | benzinga.comCitigroup Initiates Coverage of Wave Life Sciences (WVE) with Buy RecommendationJuly 16, 2025 | msn.comWAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Should You Buy?July 16, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Coverage Initiated at CitigroupJuly 16, 2025 | marketbeat.comWave Life Sciences Unveils Promising Preclinical Data for Obesity Treatment WVE-007 at ADA Scientific SessionsJuly 15, 2025 | msn.comWAVE Life Sciences (NASDAQ:WVE) Shares Down 6.5% - What's Next?July 15, 2025 | marketbeat.comLeerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24July 11, 2025 | msn.comNASDAQ:WVE Financials | Wave Life Sciences Ltd - Investing.comJuly 11, 2025 | investing.comWAVE Life Sciences (NASDAQ:WVE) Trading Up 6.8% - Should You Buy?July 9, 2025 | marketbeat.comWAVE Life Sciences Ltd. Company & People | WVE | Barron'sJuly 7, 2025 | barrons.comWave Life Sciences: Upgrading Rating To Buy After Turbulent 10 MonthsJuly 7, 2025 | seekingalpha.comWave Life Sciences: Speculative, But PromisingJuly 7, 2025 | seekingalpha.comWave Life Sciences Ltd. (WVE) - Yahoo FinanceJuly 6, 2025 | finance.yahoo.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 6, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 6, 2025 | marketbeat.comMoody Aldrich Partners LLC Increases Holdings in WAVE Life Sciences Ltd. (NASDAQ:WVE)July 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerGoldman Spotlights These 3 Stocks in Its Bullish S&P 500 OutlookBy Brian O'Connell | July 15, 2025View Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 OutlookCAPR, NTLA, WVE, and PHVS Company DescriptionsCapricor Therapeutics NASDAQ:CAPR$7.06 +0.58 (+8.95%) Closing price 04:00 PM EasternExtended Trading$7.02 -0.04 (-0.64%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Intellia Therapeutics NASDAQ:NTLA$13.60 +0.82 (+6.42%) Closing price 04:00 PM EasternExtended Trading$13.61 +0.01 (+0.07%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Pharvaris NASDAQ:PHVS$20.62 +0.57 (+2.84%) Closing price 04:00 PM EasternExtended Trading$20.43 -0.19 (-0.90%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.WAVE Life Sciences NASDAQ:WVE$8.40 +0.01 (+0.12%) Closing price 04:00 PM EasternExtended Trading$8.40 0.00 (-0.01%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
